The Egfr Tk Inhibitor Gefitinib (Iressa), but Not Erlotinib (Tarceva), Is a Substrate for Bcrp: Impact of Cellular Folate Status on Biological Activity

AuthID
 P-004-P49
5
Author(s)
Hoebe, EK
·
Jansen, G
·
Peters, GJ
Document Type
Abstract
Year published
2006
Published
in ANNALS OF ONCOLOGY, ISSN: 0923-7534
Volume: 17, Pages: 46-46 (1)
Conference
4Th International Symposium on Targeted Anticancer Therapies, Date: MAR 16-18, 2006, Location: Amsterdam, NETHERLANDS, Sponsors: Novartis, AstraZeneca, Bayer HealthCare, Centocor, Johnson & Johnson, Lilly, Merck, MSD, OSI, Schering
Indexing
Wos®
Publication Identifiers
Wos: WOS:000237800900087
Source Identifiers
ISSN: 0923-7534
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service